Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
GSK pens $50M pact to join Big Pharma peers in emerging modality
GSK will work with LTZ on myeloid cell engagers, a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
Nick Paul Taylor
Nov 19, 2025 4:40am
Genmab sheds another clinical ADC from $1.8B ProfoundBio buy
Nov 17, 2025 2:17pm
Bayer bails on Vividion tumor drug in early-stage clear-out
Nov 12, 2025 8:10am
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
Nov 6, 2025 1:26pm
AstraZeneca drops MASH drug over disappointing data
Nov 6, 2025 5:21am
TScan lays off 30% of workforce, halts solid tumor TCR trial
Nov 3, 2025 8:25am
